Literature DB >> 32118628

Genomic and Clinicopathologic Characteristics of PRKAR1A-inactivated Melanomas: Toward Genetic Distinctions of Animal-type Melanoma/Pigment Synthesizing Melanoma.

Jarish N Cohen1,2, Iwei Yeh1,2,3,4, Thaddeus W Mully1,2, Philip E LeBoit1,2,3,4, Timothy H McCalmont1,2,3,4.   

Abstract

Melanocytic tumors with inactivation of protein kinase A regulatory subunit-α (PRKAR1A) have large oval nuclei and intense pigmentation. Historically, these tumors have been categorized under various names, including epithelioid blue nevus, pigmented epithelioid melanocytoma (PEM) and animal-type melanoma. Although a subset of PEM harbor BRAF activating mutations and biallelic inactivation of PRKAR1A, there are only a few reports of melanomas, or of tumors with genomic alterations beyond those of PEMs. Herein, we describe the clinicopathologic and genetic features of 8 melanomas and tumors that lack PRKAR1α expression by immunohistochemistry but do not fit with conventional PRKAR1A-inactivated melanocytomas. These tumors tended to affect younger patients than conventional melanomas (median age=38 y) and presented as dark brown/black papules and nodules. Histopathologically, they demonstrated nodularity, sometimes in a background of conventional melanoma, and large vesicular nuclei with prominent nucleoli. With the exception of 1 case, the mitotic index was not significantly elevated. Immunohistochemically, all cases showed loss of PRKAR1α and of p16 expression. Seven tumors underwent massively parallel short read (next-generation) sequencing of a panel of 480 cancer-associated genes. Five tumors demonstrated truncating mutations of PRKAR1A and the 2 in which such mutations were not identified demonstrated loss of heterozygosity of the PRKAR1A locus. Four of the tumors harbored BRAF V600E mutations, and 1 harbored a FAM39B-BRAF gene fusion. Another harbored a GNA11 activating mutation. A MAP kinase activating mutation was not identified in the remaining case. Four tumors displayed TERT promoter mutations and chromosomal copy number changes supporting the diagnosis of melanoma. Two cases without these alterations and were classified as "high-grade PRKAR1A-inactivated melanocytomas". The 1 case with widespread metastases demonstrated mutations in TP53 and RB1. Overall, we provide the first genetic characterization of PRKAR1A-inactivated melanomas, discuss the differential diagnosis of heavily pigmented epithelioid melanocytic neoplasms, and propose a new nomenclature for such tumors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32118628     DOI: 10.1097/PAS.0000000000001458

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

1.  Novel insights into the BAP1-inactivated melanocytic tumor.

Authors:  Michele Donati; Petr Martinek; Petr Steiner; Petr Grossmann; Tomas Vanecek; Liubov Kastnerova; Isabel Kolm; Martina Baneckova; Pietro Donati; Irina Kletskaya; Antonina Kalmykova; Josef Feit; Petr Blasch; Diana Szilagyi; Alfonso Baldi; Paolo Persichetti; Anna Crescenzi; Michal Michal; Dmitry V Kazakov
Journal:  Mod Pathol       Date:  2021-12-02       Impact factor: 7.842

2.  A Blue-pigmented Lesion on the Cheek in a Three-year-old Girl: A Quiz.

Authors:  Charlotte Moreau; Anne Le Touze; Fanny Dujardin; Annabel Maruani
Journal:  Acta Derm Venereol       Date:  2021-10-28       Impact factor: 3.875

Review 3.  Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.

Authors:  Jérémy H Raymond; Zackie Aktary; Lionel Larue; Véronique Delmas
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

4.  Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation.

Authors:  Richard S P Huang; Julie Y Tse; Lukas Harries; Ryon P Graf; Douglas I Lin; Karthikeyan Murugesan; Matthew C Hiemenz; Vamsi Parimi; Tyler Janovitz; Brennan Decker; Eric Severson; Mia A Levy; Shakti H Ramkissoon; Julia A Elvin; Jeffrey S Ross; Erik A Williams
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

Review 5.  Fatal melanoma with a novel MYO5A-BRAF fusion and small associated conventional nevus: A case report and review of literature.

Authors:  Hannah E Clark; Yuan Yu Michael Huang; Gail H Vance; Ahmed K Alomari
Journal:  J Cutan Pathol       Date:  2022-06-12       Impact factor: 1.458

Review 6.  "Animal-Type Melanoma/Pigmented Epithelioid Melanocytoma": History and Features of a Controversial Entity.

Authors:  Gerardo Cazzato; Francesca Arezzo; Anna Colagrande; Antonietta Cimmino; Teresa Lettini; Sara Sablone; Leonardo Resta; Giuseppe Ingravallo
Journal:  Dermatopathology (Basel)       Date:  2021-07-05

Review 7.  The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.

Authors:  Gerardo Ferrara; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

Review 8.  Melanoma pathology: new approaches and classification.

Authors:  I Yeh; B C Bastian
Journal:  Br J Dermatol       Date:  2021-05-31       Impact factor: 11.113

9.  Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.

Authors:  Chiel F Ebbelaar; Anne M L Jansen; Lourens T Bloem; Willeke A M Blokx
Journal:  Virchows Arch       Date:  2021-04-13       Impact factor: 4.064

Review 10.  Pigmented Epithelioid Melanocytomas and Their Mimics; Focus on Their Novel Molecular Findings.

Authors:  Erol C Bayraktar; George Jour
Journal:  Biology (Basel)       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.